当前位置: 首页 >> 检索结果
共有 4957 条符合本次的查询结果, 用时 2.5416788 秒

61. Tom Shakespeare: advocating for people with disabilities.

作者: Aarathi Prasad.
来源: Lancet. 2025年

62. Cancer vaccines and the future of immunotherapy.

作者: Orrin Pail.;Matthew J Lin.;Theodora Anagnostou.;Brian D Brown.;Joshua D Brody.
来源: Lancet. 2025年
Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by protecting against cancer-causing pathogens. By contrast, therapeutic vaccines training the immune system to eliminate established tumours are now showing real promise in clinical settings. In the adjuvant setting, vaccines against melanoma and pancreatic cancer appear to be reducing minimal residual disease and relapse. In the macrometastatic setting, in-situ vaccines have induced systemic regressions in advanced-stage lung and breast cancers and lymphomas. More effective cancer vaccines are being developed through having a deeper understanding of crucial cellular factors in tumour immunology, the incorporation of newer vaccine components to effectively mobilise and activate cells, the use of omics and artificial intelligence in vaccine design, and addition of immune checkpoint blockade. In this Viewpoint, we analyse cancer vaccine trials, the strengths and limitations of different vaccine approaches, and we discuss how the next generation of cancer vaccines can help improve patient outcomes and quality of life.

63. Open letter in support of WHO.

作者: Ivana Bozicevic.;Stjepan Oreskovic.;Rieke van der Graaf.;Martin McKee.; .
来源: Lancet. 2025年405卷10497期2272-2273页

64. Challenges of the current yellow fever outbreak in Colombia.

作者: Carlos A Alvarez-Moreno.;Alfonso J Rodriguez-Morales.
来源: Lancet. 2025年405卷10497期2273页

66. Genocide in Gaza: moral and ethical failures of medical institutions.

作者: Helena Niu.;Marella Bedggood.;Matthew Jenkins.;Sana Pathan.;Daud Saeed.;Jon Jureidini.
来源: Lancet. 2025年405卷10497期2271-2272页

67. Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial.

作者: Wijnand A C Palmbergen.;Roy Beekman.;A Marijne Heeren.;Bart F L van Nuenen.;Tim W H Alleman.;Esther Verstraete.;Korné Jellema.;Wim I M Verhagen.;Leo H Visser.;Godard C W de Ruiter.;Diederik van de Beek.;Corianne A J M de Borgie.;Johannes A Bogaards.;Rob M A de Bie.;Camiel Verhamme.; .
来源: Lancet. 2025年405卷10495期2153-2163页
Surgery and corticosteroid injections are established treatments for carpal tunnel syndrome, but the optimal treatment strategy remains unclear. This study aimed to compare starting treatment with surgery versus starting with a corticosteroid injection.

68. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.

作者: Sheela Rao.;Emmanuelle Samalin-Scalzi.;Ludovic Evesque.;Meher Ben Abdelghani.;Federica Morano.;Amitesh Roy.;Laetitia Dahan.;Stefano Tamberi.;Amandeep Singh Dhadda.;Mark P Saunders.;Nathalie Casanova.;Rosine Guimbaud.;Astrid Lievre.;Joan Maurel.;Marwan Fakih.;Chuan Tian.;Jill Harrison.;Mark M Jones.;Mark Cornfeld.;Jean-Philippe Spano.;Pauline Rochefort.; .
来源: Lancet. 2025年405卷10495期2144-2152页
Retifanlimab has activity in programmed death ligand 1-positive advanced squamous cell anal carcinoma (SCAC) that has progressed on platinum chemotherapy. We aimed to prospectively assess the benefit of adding retifanlimab to initial carboplatin-paclitaxel for this disease.

69. Beyond deficit models in early childhood development science - Authors' reply.

作者: Catherine E Draper.;Günther Fink.;Dana C McCoy.;Milagros Nores.;Aisha K Yousafzai.
来源: Lancet. 2025年405卷10495期2127-2128页

70. Beyond deficit models in early childhood development science.

作者: Gabriel Scheidecker.;Tatek Abebe.;Seye Abimbola.;Nandita Chaudhary.;Willem E Frankenhuis.;Heidi Keller.;Yuko Munakata.;Bolajoko O Olusanya.;Dandara de Oliveira Ramos.;Muneera A Rasheed.
来源: Lancet. 2025年405卷10495期2127页

71. Digital acceptance and commitment therapy for fibromyalgia - Authors' reply.

作者: Lesley Arnold.;R Michael Gendreau.;Lance M McCracken.;Ben Vaughn.;Michael J Rosenbluth.
来源: Lancet. 2025年405卷10495期2126-2127页

72. Digital acceptance and commitment therapy for fibromyalgia.

作者: Dan Shan.
来源: Lancet. 2025年405卷10495期2125-2126页

73. The burden of unstable fractures in axial spondyloarthritis.

作者: Nathan Beucler.
来源: Lancet. 2025年405卷10495期2124-2125页

74. The revised Declaration of Helsinki protects healthy volunteers.

作者: Jack S Resneck.;Urban Wiesing.;Dominique Sprumont.;Johannes J M van Delden.;Ramin W Parsa-Parsi.;Amber R Comer.;Jake Young.;Otmar Kloiber.
来源: Lancet. 2025年405卷10495期2123-2124页

75. Bridging the gap in radiotherapy access in Kenya.

作者: Monicah Kitonga.;Marlene Koskei.;Lamech Koibarak.;Lincoln Sheets.
来源: Lancet. 2025年405卷10495期2122-2123页

76. Human reproduction in crisis: causes unknown.

作者: Niels E Skakkebaek.;Lærke Priskorn.;Rune Lindahl-Jacobsen.;Anna-Maria Andersson.;David M Kristensen.;Astrid Linnea Beck.;Lise Aksglaede.;Margit Bistrup Fischer.;Luiz R Franca.;Anders Juul.
来源: Lancet. 2025年405卷10495期2121-2122页

77. New evidence for common practices in carpal tunnel syndrome.

作者: Malin Zimmerman.;Lars B Dahlin.
来源: Lancet. 2025年405卷10495期2107-2109页

78. First-line immunotherapy combination in squamous cell anal carcinoma: hope in a neglected disease.

作者: Erika Martinelli.;Giulia Martini.
来源: Lancet. 2025年405卷10495期2106-2107页

79. Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer.

作者: Noura J Choudhury.;Marina C Garassino.
来源: Lancet. 2025年405卷10495期2104-2106页

80. The uncertain future of migrant and refugee health.

作者: The Lancet.
来源: Lancet. 2025年405卷10495期2103页
共有 4957 条符合本次的查询结果, 用时 2.5416788 秒